journal article·2025-12Open access

Nanocrystal-loaded dissolving microneedles: A novel transdermal strategy for long-acting tizanidine administration

Yilin Cong, Huanhuan Li, Anjali Kiran Pandya, Lalitkumar K. Vora, Yaocun Li, Fabiana Volpe-Zanutto, Alejandro J. Paredes, Abraham M. Abraham, Jiaqi Gao, Eneko Larrañeta, Nuoya Qin, Yidan Luo, Yushi Tao, Brian Quinn, Helen O. McCarthy, Ryan F. Donnelly

Abstract

Spasticity is commonly managed with tizanidine (TZN), a centrally acting α 2 -adrenergic agonist. However, its clinical application is limited by poor oral bioavailability and a short elimination half-life, necessitating frequent dosing and thereby reducing patient adherence. In this study, a trilayer dissolving microneedle array patch (MAP) incorporating TZN was developed as an alternative minimally invasive platform for long-acting transdermal delivery. TZN nanocrystals (NCs) with a mean particle size of 243 ± 21 nm and a polydispersity index (PDI) < 0.2 were successfully prepared, resulting in supersaturated solubility and an increased dissolution rate. Ex vivo permeation studies demonstrated that MAP-mediated skin penetration is essential for transdermal delivery and that NC-loaded formulations provide markedly enhanced delivery efficiency. Importantly, the in vivo pharmacokinetic evaluation in Sprague-Dawley® rats demonstrated that MAPs incorporated with NCs (C max = 229.23 ± 72.34 ng/mL, mean retention time (MRT) (52.46 ± 13.72 h)) achieved markedly improved systemic exposure (7682.36 ± 1784.77 ng/mL∗h) compared with coarse drug-loaded MAPs (AUC 0–28 days = 4936.06 ± 882.51 ng/mL∗h, p < 0.05) and intramuscular (IM) injection (AUC 0–28 days = 795.99 ± 146.94 ng/mL∗h, p < 0.05). These findings suggest that the integration of TZN NCs into dissolving MAPs represents a novel and effective transdermal strategy for the sustained systemic delivery of TZN. In addition to improving patient adherence and therapeutic outcomes in spasticity management, this platform offers a generalisable approach for enhancing the transdermal delivery of poorly soluble drugs and may inform the future design of long-acting delivery for other compounds.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (76)

Show source-provided references
1. Spasticity: a general outlook of pathogenesis and current management10.30574/ijsra.2024.13.1.1681 ↗
2. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders10.2165/00003495-199753030-00007 ↗
3. Tizanidine: advances in pharmacology & therapeutics and drug formulations10.2147/JPR.S461032 ↗
4. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects10.1016/j.clinthera.2008.12.014 ↗
5. Microneedle-mediated transdermal delivery of tizanidine hydrochloride10.1007/978-1-4939-9798-5_13 ↗
6. Donnelly · 2012
7. Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms10.1016/j.ejps.2021.105920 ↗
8. Transdermal films containing tizanidine: in vitro and in vivo evaluation10.1016/S1773-2247(14)50013-5 ↗
9. A combined approach of chemical enhancers and sonophoresis for the transdermal delivery of tizanidine hydrochloride10.1080/10717540802605053 ↗
10. Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation10.1080/08982104.2019.1684940 ↗
11. Microneedles for oral mucosal delivery–current trends and perspective on future directions10.1080/17425247.2023.2264189 ↗
12. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development10.1016/j.mser.2016.03.001 ↗
13. Donnelly · 2015
14. Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs10.1016/j.jconrel.2014.02.007 ↗
15. Intramuscular injection technique: an evidence-based approach10.7748/ns.29.4.52.e9183 ↗
16. Microneedles: a smart approach and increasing potential for transdermal drug delivery system10.1016/j.biopha.2018.10.078 ↗
17. Microarray patches: poking a hole in the challenges faced when delivering poorly soluble drugs10.1002/adfm.202005792 ↗
18. Enhanced long-acting simvastatin delivery via effervescent powder-carrying hollow microneedles and nanocrystal-loaded microneedles10.1016/j.ijpharm.2024.124691 ↗
19. Designing microneedles for intravaginal delivery: current challenges and prospects10.1007/978-981-96-3916-8_2 ↗
20. Overcoming poor aqueous solubility of drugs for oral delivery
21. The rate of solution of solid substances in their own solutions10.1021/ja02086a003 ↗
22. Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation10.3109/03639045.2016.1173051 ↗
23. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat10.1016/j.ijpharm.2007.02.030 ↗
24. Dissolving microarray patches for transdermal delivery of risperidone for schizophrenia management10.1016/j.ijpharm.2024.124342 ↗
25. Microarray patches: poking a hole in the challenges faced when delivering poorly soluble drugs10.1002/adfm.202005792 ↗
26. Calcipotriol nanosuspension-loaded trilayer dissolving microneedle patches for the treatment of psoriasis: in vitro delivery and in vivo antipsoriatic activity studies10.1021/acs.molpharmaceut.3c01223 ↗
27. Overview of milling techniques for improving the solubility of poorly water-soluble drugs
28. Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride10.1016/j.ijpharm.2021.120885 ↗
29. Polymeric microarray patches for enhanced transdermal delivery of the poorly soluble drug olanzapine10.1021/acsami.3c05553 ↗
30. Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis10.1016/j.ejpb.2020.06.025 ↗
31. Ring inserts as a useful strategy to prepare tip-loaded microneedles for long-acting drug delivery with application in HIV pre-exposure prophylaxis10.1016/j.matdes.2022.111416 ↗
32. A proposed model membrane and test method for microneedle insertion studies10.1016/j.ijpharm.2014.05.042 ↗
33. Solubility and fractionation of polyvinylpyrrolidone10.1002/pol.1952.120080508 ↗
34. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms10.1002/jps.2600561005 ↗
35. 2005
36. Validation of analytical procedures–ICH Q2 (R2)
37. Q2 (R1) validation of analytical procedures: text and methodology10.1002/9781118971147.ch5 ↗
38. Guideline · 2022
39. Validity of particle size analysis techniques for measurement of attrition of needle-shaped particles that occurs during vacuum agitated powder drying10.1039/C1AN15836H ↗
40. Dissolving microarray patches loaded with a rotigotine nanosuspension: a potential alternative to Neupro® patch10.1016/j.jconrel.2024.06.039 ↗
41. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods10.1111/j.2042-7158.2010.01022.x ↗
42. Steric stabilization of nanoparticles: size and surface properties10.1016/0378-5173(96)04486-9 ↗
43. Origin of stabilisation of aqueous foams in nanoparticle–surfactant mixtures10.1039/b811291f ↗
44. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems10.3390/pharmaceutics10020057 ↗
45. Controlled freezing and freeze drying: a versatile route for porous and micro‐/nano‐structured materials10.1002/jctb.2495 ↗
46. Physicochemical characteristics and antibacterial activities of freeze-thawed polyvinyl alcohol/andrographolide hydrogels10.1021/acsomega.2c05110 ↗
47. The measurement of the crystallinity of polymers by DSC10.1016/S0032-3861(02)00235-5 ↗
48. Structural and thermal studies of PVA: NH4I10.1016/j.jpcs.2009.06.005 ↗
49. Differential scanning calorimetry techniques: applications in biology and nanoscience
50. Thermal behavior of poly (vinyl alcohol) in the form of physically crosslinked film10.3390/polym15081843 ↗
51. The theory of ostwald ripening10.1007/BF01017860 ↗
52. Thermal degradation of olive solid waste: influence of particle size and oxygen concentration10.1016/j.resconrec.2009.04.010 ↗
53. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?10.1002/jps.21650 ↗
54. The effect of the particle size reduction on the biorelevant solubility and dissolution of poorly soluble drugs with different acid-base character10.3390/pharmaceutics15010278 ↗
55. Efficient drug delivery into skin using a biphasic dissolvable microneedle patch with water‐insoluble backing10.1002/adfm.202103359 ↗
56. A review on PLA-Based biodegradable materials for biomedical applications10.1016/j.giant.2024.100261 ↗
57. Trilayer microneedle array assisted transdermal and intradermal delivery of dexamethasone10.1016/j.ijpharm.2021.121295 ↗
58. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution10.1016/j.jconrel.2010.08.008 ↗
59. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique10.1007/s11095-010-0169-8 ↗
60. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension10.1016/j.jconrel.2018.11.002 ↗
61. Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays10.1016/j.ijpharm.2012.05.069 ↗
62. Microneedle-mediated transdermal delivery of biopharmaceuticals10.3390/pharmaceutics15010277 ↗
63. Microneedle mediated transdermal delivery of protein, peptide and antibody based therapeutics: current status and future considerations10.1007/s11095-020-02844-6 ↗
64. Hydrogel-forming microarray patches with solid dispersion reservoirs for transdermal long-acting microdepot delivery of a hydrophobic drug10.1016/j.jconrel.2023.03.003 ↗
65. Novel bilayer microarray patch‐assisted long‐acting micro‐depot cabotegravir intradermal delivery for HIV pre‐exposure prophylaxis
66. Fabrication of tizanidine loaded patches using flaxseed oil and coriander oil as a penetration enhancer for transdermal delivery10.3390/polym13234217 ↗
67. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients10.1111/j.1742-1241.2007.01660.x ↗
68. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud)10.1136/jnnp.57.11.1355 ↗
69. Dissolving microneedles: applications and growing therapeutic potential10.1016/j.jconrel.2022.05.045 ↗
70. Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis10.1016/j.jconrel.2017.07.032 ↗
71. Long-acting microneedle formulations10.1016/j.addr.2023.115055 ↗
72. Nanocrystals for controlled delivery: state of the art and approved drug products10.1080/17425247.2022.2110579 ↗
73. Formulation and evaluation of tizanidine hydrochloride loaded ethosomes for transdermal delivery
74. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization10.1080/08982104.2018.1524482 ↗
75. Atorvastatin-loaded dissolving microarray patches for long-acting microdepot delivery: comparison of nanoparticle and microparticle drug formulations
76. Transdermal patches: history, development and pharmacology10.1111/bph.13059 ↗